Live Chat
Today's Hours: 8:00am - 8:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Elisabetta Bugianesi, editor.
    Summary: The goal of this book is to promote awareness of non-alcoholic fatty liver disease (NAFLD) - which is rapidly replacing viral hepatitis as the leading cause of chronic liver disease in Europe, North and South America and Asia - and to share the latest information on evolving approaches to diagnosis and treatment. The book offers a comprehensive overview of the current topics of interest in the field, and provides clinical guidance on NAFLD through a multidisciplinary approach based on the latest scientific understanding of this multisystemic disease, involving the expertise of specialists including hepatologists, diabetologists, and cardiologists. The respective contributions address various aspects, including the newly released international guidelines, novel diagnostic modalities, and new experimental drugs. The work will appeal to a broad readership, from residents in internal medicine to specialists.

    Contents:
    Introduction
    Obesity and NAFLD: same problem? The burden of NAFLD worldwide
    Histo-pathology of NAFLD
    NAFLD and insulin resistance: a multisystemic
    Etiopathogenesis of NAFLD: diet, gut and NASH
    Etiopathogenesis of NAFLD: molecular mechanisms of fibrogenesis
    The natural history of NAFLD: Environmental vs Genetic Risk Factors
    NAFLD and endocrine disease: clinical implications
    NAFLD and Cardiovascular Disease: clinical implications
    NAFLD, Hepatocellular Carcinoma and extrahepatic cancers
    NAFLD in children: implications for the future
    Diagnostic algorithm for the identification of NAFLD in primary care
    Non-Invasive diagnostic approach to NASH: Biological Markers
    Non-Invasive diagnostic approach to NASH: Radiological Diagnostics
    Dietary approach to NAFLD
    Physical Activity in NAFLD: what and how much? Pharmacological Therapy of NASH
    Bariatric Surgery and NASH: a feasible option? Liver transplantation and NASH
    Unmet needs and future goals.
    Digital Access Springer 2020
  • Article
    Chard RL, Finklestein JZ, Sonley MJ, Nesbit M, McCreadie S, Weiner J, Sather H, Hammond GD.
    Med Pediatr Oncol. 1978;4(3):263-73.
    One hundred-sixty-three children with acute nonlymphocytic leukemia (ANLL) were treated with a multiple-drug induction program (PATCO) consisting of prednisone (PDN), cytosine arabinoside ((Ara-C), 6-thioguanine (6-TG), cyclophosphamide (CPM), and Oncovin (VCR). Ninety-six, 59%, obtained a remission. Remission was maintained with daily 6-TG and four-day pulses of Ara-C and CPM with a single dose of VCR every 28 days. The median duration of remission was 11.5 months. Certain prognostic factors affected induction rate and remission duration. Initial white blood count (WBC) was a significant factor in achieving a remission, whereas age, sex, and type of ANLL had no effect. Initial WBC, age, and sex had a significant effect on remission duration, but type of ANLL had no effect. Relapsing patients were treated with daunomycin and 5-azacytidine. The reinduction rate was 53% with a median second remission duration of 190 days. Overall survival for the 163 patients is 55.4% at 12 months, 31.5% at 24 months, 21.4% at 36 months, and 19% at 48 months.
    Digital Access Access Options